Nav: Home

Oklahoma researchers find that a biological 'good guy' has a dark side

May 04, 2016

A pair of Oklahoma Medical Research Foundation scientists have discovered that an enzyme previously thought only to be beneficial could, in fact, pose significant danger to developing embryos. The new research could have implications not only for prenatal development but also for treating lymphedema and liver damage resulting from acetaminophen overdose.

Using genetically engineered mouse embryos, OMRF's Courtney Griffin, Ph.D., and Patrick Crosswhite, Ph.D., looked at what would happen if they removed a protein that determines how genes get turned on and off during blood vessel development.

The scientists found a marked increase in the activity of plasmin, an enzyme that is known to help break up blood clots and promote blood vessel development. But in a developing embryo, said Griffin, too much of the enzyme can pose a threat.

"Plasmin has always been seen in a positive light, but we're not finding any beneficial aspects of it in early development," said Griffin. "In fact, excessive plasmin does dangerous things in a growing embryo."

The OMRF researchers also found that liver damage could ensue in embryos when the protein that suppresses plasmin activity--known as CHD4--was absent. Too much plasmin makes liver blood vessels fragile and prone to bleeding. They also found that excess plasmin could be harmful to the lymph system, an essential part of the immune system, by breaking down blood clots that help the lymphatic system function properly.

With this new information, Griffin and Crosswhite will study plasmin behavior later in gestation and in adults. They'll investigate how high concentration of plasmin may contribute to conditions such as lymphedema, a painful lymph disorder marked by swelling in the arms and legs. They'll also look at whether CHD4 continues protecting liver blood vessels from plasmin damage after birth.

More research is needed, said Griffin, but the findings may lead to clinical use of plasmin-blocking compounds after acetaminophen overdose. Acetaminophen is the active ingredient in Tylenol, and overdose is a leading cause of liver damage in the U.S., resulting in up to 70,000 hospitalizations a year. "Excessive plasmin activity in the liver has been linked to acetaminophen overdose," said Crosswhite, "and we suspect this plasmin may make liver blood vessels dangerously weak."

"This work is innovative and creative, from the results to the interpretation and conclusions," said Rodger McEver, M.D., chair of OMRF's Cardiovascular Biology Research Program. "These scientists were able to show that plasmin is really important in ways that hadn't been discovered before. It gives us new information and is great basic science, but the data could be clinically relevant to treating acetaminophen toxicity in humans."

The new findings appear in the May 3 issue of the Journal of Clinical Investigation.
-end-
Other OMRF contributors to the paper include Sathish Srinivasan, Ph.D., Lijun Xia, M.D., Ph.D., and Siqi Gao, as well as former OMRF employees Carol Curtis, Ph.D., and Joanna Podsiadlowska.

Funding for the research was made possible by grant number HL111178, HD083418 and HL085607 from the National Institutes of Health and grant number 15POST21180005 from the American Heart Association.

High-resolution photos of Courtney Griffin, Ph.D., and Patrick Crosswhite, Ph.D., are available for download here: http://omrf.org/newsgallery/griffincrosswhite/



About OMRF


OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus and cardiovascular disease.

Oklahoma Medical Research Foundation

Related Blood Clots Articles:

Cellular senescence is associated with age-related blood clots
Cells that become senescent irrevocably stop dividing under stress, spewing out a mix of inflammatory proteins that lead to chronic inflammation as more and more of the cells accumulate over time.
New guidance on potentially fatal blood clots published today
The European Society of Cardiology (ESC) Guidelines on acute pulmonary embolism are published online today in European Heart Journal, and on the ESC website.
One in five haematological cancer patients suffer blood clots or bleeding
In the years following haematological cancer, one in five survivors suffer a blood clot or bleeding which requires hospital treatment.
Targeting inflammation to better understand dangerous blood clots
Forty percent of people who develop venous thromboembolism don't know what caused it.
Impeding white blood cells in antiphospholipid syndrome reduced blood clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.
Research unlocks biomechanical mystery behind deadly blood clots
Researchers at the University of Sydney have used biomechanical engineering techniques to unlock the mystery surrounding the mechanical forces that influence blood clotting.
HRT tablets associated with increased risk of blood clots
Hormone replacement therapy (HRT) tablets are associated with a higher risk of rare but serious blood clots (known as venous thromboembolism or VTE), finds a large study in The BMJ today.
HRT tablets increase risk of blood clots in women
Women who use certain types of hormone replacement therapy (HRT) are at a higher risk of developing potentially life-threatening blood clots, new research has confirmed.
How and why blood clots shrink
In an article published in Nature Communications, researchers at the University of California, Riverside and the University of Pennsylvania School of Medicine used high-powered microscopy and rheometry -- the measurement of how materials become deformed in response to applied force -- to view the blood clotting process in real time and at the cellular level.
Can height increase risk for blood clots in veins?
Risk of blood clots in the veins was associated with height, with the lowest risk in participants who were five feet tall or shorter.
More Blood Clots News and Blood Clots Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.